Skip to main content
Clinical Trials/NCT05229029
NCT05229029
Active, Not Recruiting
Phase 2

A Multicenter, Randomized, Double-blind Clinical Trial of TCM in Reducing CRF Caused by Chemotherapy in Cancer Patients

Peking University Cancer Hospital & Institute1 site in 1 country196 target enrollmentApril 2, 2020

Overview

Phase
Phase 2
Intervention
TCM Formula
Conditions
Cancer-related Problem/Condition
Sponsor
Peking University Cancer Hospital & Institute
Enrollment
196
Locations
1
Primary Endpoint
Fatigue score
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is a multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of Chinese herbal compound in improving fatigue symptoms and quality of life in patients with chemotherapy.

Detailed Description

In this study, symptomatic indicators and quality of life were used as the main evaluation indicators. Patients with moderate to severe CRF who received dual drug chemotherapy were given traditional Chinese medicine compound and placebo intervention respectively. The data of fatigue symptoms, quality of life, sleep quality, blood routine test, liver and kidney function were observed and compared, so as to verify the traditional Chinese medicine compound prescription in improving the CRF symptoms and quality of life of chemotherapy patients validity.

Registry
clinicaltrials.gov
Start Date
April 2, 2020
End Date
June 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Peking University Cancer Hospital & Institute
Responsible Party
Principal Investigator
Principal Investigator

Sun Hong

Director

Peking University Cancer Hospital & Institute

Eligibility Criteria

Inclusion Criteria

  • Malignant tumor patients with pathological diagnosis
  • Men and women aged 18-75
  • KPS score ≥ 70, expected survival time more than 6 months
  • The function of heart, lung, liver and kidney was normal
  • Hemoglobin ≥ 8g
  • Neuroendocrine function is normal
  • BMI ≥ 18.
  • Cancer pain, VAS score \< 3
  • Fatigue score ≥ 4
  • syndrome differentiation is deficiency of Qi and blood

Exclusion Criteria

  • Brain metastases with Symptomatic
  • Mental disease
  • Severe infection
  • Insomniacs
  • Pregnant or lactating women

Arms & Interventions

TCM decoction

Compound granules of Traditional Chinese Medicine

Intervention: TCM Formula

placebo

Placebo only

Intervention: Placebo

Outcomes

Primary Outcomes

Fatigue score

Time Frame: 21 days

Self-assessed 24-hour fatigue symptom score. According to the NCCN fatigue guide, the score is 0-10 points, 0 points means no fatigue, 10 points means the most serious fatigue that can be imagined.

Study Sites (1)

Loading locations...

Similar Trials